<DOC>
	<DOCNO>NCT00210366</DOCNO>
	<brief_summary>The main objective trial assess therapeutic activity idarubicin salvage treatment patient recurrent progressive lymphoma central nervous system .</brief_summary>
	<brief_title>Salvage Therapy With Idarubicin Relapsing CNS Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Histological cytological diagnosis nonHodgkin 's lymphoma Disease exclusively localise CNS first diagnosis failure Progressive recurrent disease Previous treatment HDMTX contain CHT and/or RT Presence least one target lesion , bidimensionally measurable Age 18 75 year ECOG performance status &lt; 3 ( Appendix 1 ) . No known HIV disease immunodeficiency HBsAgnegative Ab antiHCVnegative patient . Adequate bone marrow function ( plt &gt; 100000 mm3 , Hb &gt; 9 g/dl , ANC &gt; 2.000 mm3 ) Adequate renal function ( serum creatinine &lt; 2 time UNL ) Adequate hepatic function ( SGOT/SGPT &lt; 3 time UNL , bilirubin alkaline phosphatase &lt; 2 time UNL ) Adequate cardiac function ( VEF â‰¥ 50 % ) Absence psycological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule Nonpregnant nonlactating status female patient . Adequate contraceptive measure study participation sexually active patient childbearing potential . No previous concurrent malignancy sit exception surgically cure carcinoma insite cervix basal squamous cell carcinoma skin neoplasm without evidence disease since least 5 year . No concurrent treatment experimental drug . Informed consent sign patient registration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>